Adjuvant treatment with dabrafenib plus trametinib prolongs relapse-free survival (RFS) in patients with resected stage III BRAF V600-mutant melanoma, according to a 5-year analysis of the COMBI-AD* study presented at the ASCO20 Virtual Scientific Program.
Prophylaxis treatment with voriconazole appears to be safe and effective, with an efficacy comparable to literature data for risk of invasive fungal infection with posaconazole antifungal prophylaxis, in patients with acute leukaemia undergoing chemotherapy, reports a study.
Use of dupilumab appears to confer benefits in patients with bullous pemphigoid (BP), results of a recent study have shown. Treatment has resulted in disease clearance or satisfactory response in majority of the patients, including those in whom previous conventional therapy has failed.
No substantial difference in infection risk is seen between biologics and nonbiologics among children with psoriasis, reveals a recent study. There is also no robust difference between systemic treatment and phototherapy.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.